BLAINJECTIONINJECTABLEPriority Review
Approved
Mar 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
DUPIXENT (dupilumab) by Regeneron is interleukin 4 receptor alpha antagonists [moa]. Approved for interleukin-4 receptor alpha antagonist [epc]. First approved in 2017.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DUPIXENT (dupilumab) is a monoclonal antibody that blocks interleukin-4 receptor alpha, reducing immune-mediated inflammation. It treats multiple allergic and inflammatory conditions including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. The drug addresses a broad inflammatory pathway shared across multiple disease states, enabling a one-molecule-many-indications strategy.
Peak
Peak lifecycle stage indicates mature commercial organization with established sales infrastructure, strong reimbursement networks, and focus on market penetration and indication expansion.
Mechanism of Action
Interleukin 4 Receptor alpha Antagonists
Pharmacologic Class:
Interleukin-4 Receptor alpha Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis
Started Oct 2026
520 enrolled
Atopic Dermatitis
Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
Started Sep 2026
24 enrolled
Metastatic Colorectal CancerLiver Metastases
The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
Started Aug 2026
350 enrolled
COPD (Chronic Obstructive Pulmonary Disease)
This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization
Started Jun 2026
754 enrolled
Chronic Obstructive Pulmonary Disease (COPD)
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy Participants
Started Jun 2026
40 enrolled
Healthy Volunteers
Worked on DUPIXENT at Regeneron? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.